Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

ACADIA Pharmaceuticals Inc. (ACAD), Rite Aid Corporation (RAD) & More: Are These Top Performers Still a “Buy”?

I am looking at the top performers from my portfolio over the last year, and deciding whether or not it is time to take profits; many of these stocks you too might own.

Using CAPS

ACADIA Pharmaceuticals Inc. (ACAD)I began using Motley Fool’s “CAPS” late last year as a way for readers to track my new positions and to show the outcome of my investments that were chosen based on the information found in my book, Taking Charge With Value Investing (McGraw-Hill, 2013).

The CAPS scores allow you to track your selections up against the market, with perfection being 100.00. Moreover, you gain a point for every percentage point that your selection outperforms its tracked index. Here are my current top four CAPS (portfolio) performers.

Company Start Price Stock Gain Index Gain CAPS Score
ACADIA Pharmaceuticals Inc.  (NASDAQ:ACAD) $6.09 203.94% 6.43% 197.52
Rite Aid Corporation (NYSE:RAD) $1.23 128.16% 11.93% 116.23
Restoration Hardware Holdings Inc (NYSE:RH) $37.60 102.13% 4.1% 98.03
Responsys Inc (NASDAQ:MKTG) $7.78 83.55% 7.8% 75.74

A Biotech That’s Not Done Yet

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has led the charge in my portfolio, and on My CAPS, since buying at $6.09. Over the last year it is trading higher by 930%. Therefore, many might assume that it should be sold.

Since the FDA is allowing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to bypass Phase 3 trials for its Parkinson’s disease psychosis drug pimavanserin, it will most likely be available in the market early next year. The product will be the only approved drug for this indication, and analysts anticipate that it will be used for several off-label indications as well.

With a market cap of $1.4 billion and peak sales potential of $2 billion, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is still very cheap. As a result, I cannot justify selling it just yet. In fact, I recently bought more at $16.75.

Possible Short-Term Pain, But Long-Term Gain

Rite Aid Corporation (NYSE:RAD) has pulled back by $0.45 since announcing earnings last month, although it posted its third consecutive profit that beat expectations. After a 175% gain since its 52-week lows, I think this pullback is healthy but also temporary.

In a recent article I explained why new generic introductions prove that the best days are yet to come. Thus, I believe this is still a great long-term buy. However, if you are looking for short-term or an immediate producer of gains to your holdings, Rite Aid Corporation (NYSE:RAD) may not be the best pick. This is definitely a long-term and volatile play.

Don’t Let Gains Scare You, This Stock Is Cheap!

Restoration Hardware Holdings Inc (NYSE:RH) is one of my favorite plays in the market. It is growing revenue by more than 30% without expanding its stores. This is a company that grows solely through comparable store sales, which is an incredible feat to accomplish.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.